TREATMENT OF RELAPSED T CELL LYMPHOMAS WITH RECOMBINANT A INTERFERON ALPHA

以前的试验已经证明了重组α干扰素的活性 在皮肤T细胞淋巴瘤患者中。最初的试验使用了 干扰素的最大耐受量，即每平方米5000万个单位 每周给药三次。这项研究中的大多数患者都需要剂量 由于毒性过大而减少；虽然部分反应 在大约50%的患者中出现，他们是有限的 持续时间，没有看到完全的反应。这次审判是一次尝试 通过以下方式提高完全响应率和响应持续时间 连续5天每天服用大剂量干扰素 之后是两周的休息期。同样在这项研究中，人们希望 对无反应或仅有症状的患者增加剂量 部分反应。

Previous trials have demonstrated activity of recombinant alpha interferon in patients with cutaneous T cell lymphomas. The initial trials used interferon at its maximal tolerated dose, that is, 50 million units per m2 given three times per week. Most patients on this study required dose reduction because of excessive toxicity; and although partial responses were seen in approximately 50 percent of patients, they were of limited duration, and no complete responses were seen. This trial is an attempt to increase the complete response rate and the response duration by administering high doses of interferon daily for five consecutive days followed by a two-week rest period. Also in this study, it was hoped to increase the dose in those patients who were not responding or who had only a partial response.